FR2482967A1 - Nouveaux derives de l'imidazo-rifamycine, leur procede de preparation et leur application en therapeutique - Google Patents

Nouveaux derives de l'imidazo-rifamycine, leur procede de preparation et leur application en therapeutique Download PDF

Info

Publication number
FR2482967A1
FR2482967A1 FR8110058A FR8110058A FR2482967A1 FR 2482967 A1 FR2482967 A1 FR 2482967A1 FR 8110058 A FR8110058 A FR 8110058A FR 8110058 A FR8110058 A FR 8110058A FR 2482967 A1 FR2482967 A1 FR 2482967A1
Authority
FR
France
Prior art keywords
existent
formula
rifamycin
hydrogen atom
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR8110058A
Other languages
English (en)
French (fr)
Other versions
FR2482967B1 (enExample
Inventor
Egidio Marchi
Lauretta Montecchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alfa Farmaceutici SpA
Original Assignee
Alfa Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfa Farmaceutici SpA filed Critical Alfa Farmaceutici SpA
Publication of FR2482967A1 publication Critical patent/FR2482967A1/fr
Application granted granted Critical
Publication of FR2482967B1 publication Critical patent/FR2482967B1/fr
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
FR8110058A 1980-05-22 1981-05-20 Nouveaux derives de l'imidazo-rifamycine, leur procede de preparation et leur application en therapeutique Granted FR2482967A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT03429/80A IT1154655B (it) 1980-05-22 1980-05-22 Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica

Publications (2)

Publication Number Publication Date
FR2482967A1 true FR2482967A1 (fr) 1981-11-27
FR2482967B1 FR2482967B1 (enExample) 1985-03-29

Family

ID=11107198

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8110058A Granted FR2482967A1 (fr) 1980-05-22 1981-05-20 Nouveaux derives de l'imidazo-rifamycine, leur procede de preparation et leur application en therapeutique

Country Status (25)

Country Link
US (1) US4341785A (enExample)
JP (1) JPS5711987A (enExample)
AR (1) AR226212A1 (enExample)
AT (1) AT373599B (enExample)
AU (1) AU537093B2 (enExample)
BE (1) BE888895A (enExample)
CA (1) CA1142518A (enExample)
CH (1) CH648037A5 (enExample)
DE (1) DE3120460A1 (enExample)
DK (1) DK157876C (enExample)
EG (1) EG14891A (enExample)
ES (1) ES8203388A1 (enExample)
FI (1) FI69467C (enExample)
FR (1) FR2482967A1 (enExample)
GB (1) GB2079270B (enExample)
GR (1) GR75640B (enExample)
IE (1) IE51204B1 (enExample)
IT (1) IT1154655B (enExample)
LU (1) LU83376A1 (enExample)
NL (1) NL187022C (enExample)
NO (1) NO155622C (enExample)
PH (2) PH17207A (enExample)
PT (1) PT73064B (enExample)
SE (1) SE453089B (enExample)
ZA (1) ZA813430B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0161534A3 (en) * 1984-05-15 1987-03-04 Alfa Farmaceutici S.P.A. New process for the synthesis of pyrido-imidazo-refamycins

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1264494B1 (it) * 1993-03-23 1996-09-24 Alfa Wassermann Spa Uso di rifaximin e di formulazioni che la contengono nel trattamento delle dispepsie gastriche originate da helicobacter
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US5981522A (en) * 1995-09-01 1999-11-09 Kaneka Corporation Treatment of disease caused by infection of Helicobacter
ES2237809T3 (es) * 1997-02-28 2005-08-01 Kaneka Corporation Medicina curativa para la enfermedad causada por infeccion de helicobacter.
AU2002360416A1 (en) * 2001-11-21 2003-06-10 Activbiotics, Inc. Targeted therapeutics and uses thereof
AU2002364162A1 (en) * 2001-12-13 2003-06-30 Activbiotics, Inc. Sulfhydryl rifamycins and uses thereof
AU2003276254A1 (en) * 2002-11-05 2004-06-07 Piero Chiarelli Controlled and continued delivery of rifaximin and/or other substances
US7820652B2 (en) * 2003-09-24 2010-10-26 Activbiotics Pharma, Llc Regimen for the administration of rifamycin-class antibiotics
US7923553B2 (en) * 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
US7902206B2 (en) * 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US7906542B2 (en) * 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
US20080262024A1 (en) * 2003-11-07 2008-10-23 Giuseppe Claudio Viscomi Rifaximin compositions and method of use
US7256187B2 (en) * 2004-03-10 2007-08-14 Cumbre Pharmaceuticals Inc. Rifamycin C-11 oxime derivatives effective against drug-resistant microbes
US7265107B2 (en) * 2004-03-10 2007-09-04 Cumbre Pharmaceuticals Inc. Rifamycin C-11 oxime cyclo derivatives effective against drug-resistant microbes
US7202246B2 (en) * 2004-06-09 2007-04-10 Cumbre Pharmaceuticals Inc. Spiro-rifamycin derivatives targeting RNA polymerase
US8003118B2 (en) * 2005-03-02 2011-08-23 Kodsi Robert E Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis
US20060210492A1 (en) * 2005-03-02 2006-09-21 Kodsi Robert E Use of rifaximin for treatment and prevention of periodontal conditions
US20060210483A1 (en) * 2005-03-02 2006-09-21 Kodsi Robert E Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections
ES2522895T3 (es) * 2005-03-03 2014-11-19 Alfa Wassermann S.P.A. Nuevas formas polimorfas de rifaximina, procedimientos para su producción y uso de las mismas en preparados medicinales
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
EP1928890B1 (en) 2005-08-11 2013-04-03 Targanta Therapeutics Inc. Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections
DK1996710T3 (da) 2006-03-09 2019-10-07 Salix Pharmaceuticals Inc Rifaximin-præparat mod rektal dysfunktion
MX2009001342A (es) 2006-08-02 2009-08-31 Salix Pharmaceuticals Inc Composiciones y metodos para el tratamiento de proctosigmoiditis por radiacion.
ITMI20061692A1 (it) 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
EP2069363B1 (en) * 2006-09-22 2013-03-20 Cipla Ltd. Rifaximin in an amorphous form
US20080161337A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Chronic Prostatitis
US20080159987A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Restless Legs Syndrome
ITMI20071241A1 (it) * 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
SI2011486T1 (sl) 2007-07-06 2012-10-30 Lupin Ltd Farmacevtski sestavki rifaksimina
JP5755878B2 (ja) 2007-07-06 2015-07-29 ルパン リミテッドＬｕｐｉｎ Ｌｉｍｉｔｅｄ リファキシミンの薬剤組成物
US7709634B2 (en) * 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
EA021176B1 (ru) * 2008-02-25 2015-04-30 Сэликс Фармасьютиклз, Лтд. Полиморфная форма рифаксимина и её применение
US8486956B2 (en) 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
US11779571B2 (en) 2008-02-26 2023-10-10 Salix Pharmaceuticals, Inc. Methods for treating irritable bowel syndrome (IBS)
KR20100122937A (ko) 2008-02-26 2010-11-23 샐릭스 파마슈티컬스 리미티드 장 질환의 치료 방법
EP2294012B1 (en) 2008-05-07 2014-07-09 Salix Pharmaceuticals, Ltd. Administration of a bowel cleanser and an antibiotic for the treatment of bowel disease
WO2010019511A2 (en) 2008-08-13 2010-02-18 Targanta Therapeutics Corp. Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections
AU2009297562B2 (en) 2008-09-26 2015-04-23 Alfasigma S.P.A. Agent for preventing and/or treating functional gastrointestinal disorder
US12285414B2 (en) 2008-10-02 2025-04-29 Salix Pharmaceuticals, Inc. Methods of treating hepatic encephalopathy
HRP20240317T1 (hr) 2008-10-02 2024-06-07 Salix Pharmaceuticals, Ltd. Liječenje hepatičke encefalopatije uporabom rifaksimina
AU2009326167A1 (en) 2008-12-10 2010-06-17 Cipla Limited Rifaximin complexes
IT1397617B1 (it) * 2009-04-20 2013-01-18 Alfa Wassermann Spa Nuovi derivati della rifamicina
EP3964066A1 (en) 2009-06-02 2022-03-09 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
EP2475392A4 (en) 2009-09-13 2013-01-09 Salix Pharmaceuticals Ltd METHOD FOR TREATING IRRITATION SYNDROME
WO2011051971A2 (en) 2009-10-27 2011-05-05 Lupin Limited Solid dispersion of rifaximin
RU2012126084A (ru) 2009-11-23 2013-12-27 Сипла Лимитед Пенная композиция для местного применения
US8952159B2 (en) 2009-12-28 2015-02-10 Silvio Massimo Lavagna Method for the production of amorphous rifaximin
AU2011218129A1 (en) 2010-02-18 2012-08-23 Board Of Regents Of The University Of Texas System Methods for treating infection
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
US9211258B2 (en) 2010-03-10 2015-12-15 Lupin Limited Rifaximin ready-to-use suspension
MX345697B (es) 2010-07-12 2017-02-13 Salix Pharmaceuticals Ltd Formulaciones de rifaximina y usos de las mismas.
US8759513B2 (en) 2010-09-13 2014-06-24 Sequent Scientific Limited Polymorphic form of rifaximin and process for its preparation
KR20140026379A (ko) 2011-02-11 2014-03-05 샐릭스 파마슈티컬스 리미티드 리팍시민의 형태 및 이의 용도
AU2012251385A1 (en) 2011-05-02 2013-11-21 Ranbaxy Laboratories Limited Rifaximin dimethylformamide solvate
ITMI20110890A1 (it) 2011-05-19 2012-11-20 A M S A Anonima Materie Sint & Affini S P A Polimorfo di rifaximina e processo per la sua preparazione
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
RU2496475C2 (ru) 2011-10-26 2013-10-27 Александр Васильевич Иващенко Фармацевтическая композиция и набор для лечения бактериальных инфекций
AU2012332211B2 (en) 2011-11-02 2016-11-24 Salix Pharmaceuticals, Ltd. Methods for treating irritable bowel syndrome (IBS) and infections
JP2015509105A (ja) * 2012-01-25 2015-03-26 サリックス ファーマスーティカルズ，リミテッド リファキシミン誘導体及びその使用
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
US9849090B2 (en) 2012-12-12 2017-12-26 Sun Pharmaceutical Industries Limited Pharmaceutical compositions of rifaximin
WO2014140995A2 (en) 2013-03-15 2014-09-18 Alfa Wassermann S.P.A. Method for diagnosing vaginal infections
KR20150129691A (ko) 2013-03-15 2015-11-20 알파 와셔만 에스.피.아. 질 감염증의 치료에 사용하기 위한 리팍시민
PT2983647T (pt) 2013-04-12 2020-11-09 Alfasigma Spa Administração de aine e composições, métodos e sistemas relacionados
US9018225B1 (en) 2013-07-26 2015-04-28 Novel Laboratories Rifaximin crystalline forms and methods of preparation thereof
EP2927235B1 (en) 2014-03-31 2017-02-08 Euticals S.P.A. Polymorphic mixture of rifaximin and its use for the preparation of solid formulations
WO2015159275A2 (en) * 2014-04-19 2015-10-22 Granules India Limited An improved process for the preparation of rifamycin derivatives
EP3140313B1 (en) 2014-05-04 2020-02-26 Salix Pharmaceuticals, Inc. Ibs microbiota and uses thereof
PT3143027T (pt) 2014-05-12 2019-09-20 Alfasigma Spa Nova forma de cristal solvatado de rifaximina, produção, composições e utilização dos mesmos
EP2982764A1 (en) 2014-08-05 2016-02-10 ALFA WASSERMANN S.p.A. Identification of vaginal bacteria
US9988398B2 (en) 2016-06-07 2018-06-05 Cadila Healthcare Limited Crystalline form of rifaximin and process for its preparation
EP4137132A1 (en) 2016-09-30 2023-02-22 Salix Pharmaceuticals, Inc. Solid dispersion forms of rifaximin
IT201700091912A1 (it) * 2017-08-08 2019-02-08 Biofer Spa Nuove pirido-imidazo rifamicine
WO2019003076A1 (en) 2017-06-26 2019-01-03 Biofer S.P.A. PYRIDO-IMIDAZO-RIFAMYCIN DERIVATIVES AS ANTIBACTERIAL AGENT

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2426690A2 (fr) * 1978-06-09 1979-12-21 Archifar Lab Chim Farm Composes de rifamycine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE273377C (enExample) *
AT273377B (de) * 1967-03-01 1969-08-11 Lepetit Spa Verfahren zur Herstellung von neuen Rifamycinen
AT344898B (de) * 1975-06-13 1978-08-10 Archifar Ind Chim Trentino Verfahren zur herstellung neuer rifamycin-verbindungen
DK345977A (da) * 1976-09-30 1978-03-31 Archifar Ind Chim Trentino G rifamycinforbindelser og fremgangsmaade til deres fremstillin
CH629212A5 (it) * 1976-10-18 1982-04-15 Erba Farmitalia Procedimento per la preparazione di composti di rifamicina.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2426690A2 (fr) * 1978-06-09 1979-12-21 Archifar Lab Chim Farm Composes de rifamycine

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0161534A3 (en) * 1984-05-15 1987-03-04 Alfa Farmaceutici S.P.A. New process for the synthesis of pyrido-imidazo-refamycins

Also Published As

Publication number Publication date
NL187022C (nl) 1991-05-01
ZA813430B (en) 1982-06-30
ES502906A0 (es) 1982-04-01
DK157876B (da) 1990-02-26
FI69467C (fi) 1986-02-10
FI811565L (fi) 1981-11-23
IT1154655B (it) 1987-01-21
PH18704A (en) 1985-09-05
LU83376A1 (fr) 1981-09-11
AU537093B2 (en) 1984-06-07
CA1142518A (en) 1983-03-08
ES8203388A1 (es) 1982-04-01
IE811139L (en) 1981-11-22
GB2079270B (en) 1984-01-18
NL187022B (nl) 1990-12-03
SE453089B (sv) 1988-01-11
PT73064B (en) 1982-07-05
SE8103216L (sv) 1981-11-23
DE3120460C2 (enExample) 1990-12-13
PH17207A (en) 1984-06-19
GB2079270A (en) 1982-01-20
JPS6123192B2 (enExample) 1986-06-04
GR75640B (enExample) 1984-08-02
DK224781A (da) 1981-11-23
AU7065581A (en) 1981-11-26
JPS5711987A (en) 1982-01-21
BE888895A (fr) 1981-09-16
IT8003429A0 (it) 1980-05-22
NL8102290A (nl) 1981-12-16
ATA222781A (de) 1983-06-15
FI69467B (fi) 1985-10-31
US4341785A (en) 1982-07-27
FR2482967B1 (enExample) 1985-03-29
CH648037A5 (de) 1985-02-28
AT373599B (de) 1984-02-10
IE51204B1 (en) 1986-10-29
AR226212A1 (es) 1982-06-15
EG14891A (en) 1985-12-31
NO155622B (no) 1987-01-19
DK157876C (da) 1990-07-30
DE3120460A1 (de) 1982-03-11
NO155622C (no) 1987-04-29
NO811731L (no) 1981-11-23
PT73064A (en) 1981-06-01

Similar Documents

Publication Publication Date Title
FR2482967A1 (fr) Nouveaux derives de l'imidazo-rifamycine, leur procede de preparation et leur application en therapeutique
EP0036812B1 (fr) Nouveaux dérivés des céphalosporines, leur procédé de préparation et les médicaments utilisables comme antibiotiques qui contiennent lesdits dérivés
BE851310A (fr) Nouveaux derives de la tetrahydro-equinocandine b
EP0253738A1 (fr) Dérivés du taxol, leur préparation et les compositions pharmaceutiques qui les contiennent
FR2477016A1 (fr) Compositions pharmaceutiques a base de derives de mitomycine pour le traitement de maladie neoplastique chez les animaux
FR2676738A1 (fr) Nouveau derive organique de metal de transition a structure porphyrinique, composition therapeutique le contenant, en particulier a activite hypoglycemiante.
EP0533827B1 (fr) Nouveaux derives de l'oxazole, leur preparation et les compositions pharmaceutiques qui les contiennent
CA1094547A (fr) Procede de preparation de derives de l'acide 3- carbamoyloxymethyl 7-(amino thiazolyl acetamido) cephalosporanique
EP0044238B1 (fr) Dérivés de céphalosporines sulfoxydes, procédé de préparation et compositions pharmaceutiques en contenant
EP0061397B1 (fr) Nouveaux dérivés solubles N2 substitués de la diamino-2,4-benzyl-5-pyrimidines, leur procédé de préparation et médicaments les contenant
FR2502627A1 (fr) Derives thioliques de l'erythromycine a activite therapeutique, procede de preparation et produits pharmaceutiques dans lesquels ils apparaissent
FR2474503A1 (fr) Composes intermediaires utiles pour l'obtention de la spectinomycine et de ses analogues ainsi que l'utilisation de ces produits
FR2519988A1 (fr) Derives thioliques de l'erythromycine a activite therapeutique, procede de preparation et produits pharmaceutiques dans lesquels ils apparaissent
FR2492385A1 (fr) Nouveaux composes cytostatiques derives de la vinblastine, leur procede de preparation et composition pharmaceutique les contenant
FR2492384A1 (fr) Procede de preparation de nouveaux composes cytostatiques et compositions pharmaceutiques les contenant
WO1996004299A1 (fr) Derives de streptogramine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2591598A1 (fr) Nouveaux derives d'acide ceph-3-em-4-carboxylique, leur preparation et medicaments les contenant
EP0269512B1 (fr) Dérivés des céphalosporines à pharmacocinétique améliorée, procédé pour leur préparation et compositions pharmaceutiques les contenant
FR2504134A1 (fr) Nouveaux derives du nitroimidazole, un procede pour leur preparation et compositions therapeutiques trichomonoacides en contenant
BE887456R (fr) Procede de production de composes intermediaires pour l'obtention de la spectinomycine et de ses analogues et produits de ce procede
BE876466A (fr) Derive de l'acide penicillanique et son procede de preparation
BE845520R (fr) Derives penam et leur preparation
KR20010029475A (ko) 약제학적 화합물의 제조 방법
CH631461A5 (en) Semi-synthetic derivatives of 4''-sulphonylaminooleandomycin
BE896512A (fr) Nouveaux derives de la pleuromutiline, leur preparation et leur utilisation comme medicaments